Watch The Film In
A Theatre Near You
I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font.
Host A Screening
I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. Feel free to drag and drop me anywhere you like on your page. I’m a great place for you to tell a story and let your users know a little more about you.
RICK DOBLIN Ph.d.
Multidisciplinary Association for Psychedelic Studies (MAPS)
Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and empty rooms from three children who are all in college.
Dennis Mckenna ph.d.
McKenna received his Master's degree in botany at the University of Hawaii in 1979. He received his doctorate in botanical sciences in 1984 from the University of British Columbia, where he wrote a dissertation entitled Monoamine oxidase inhibitors in Amazonian hallucinogenic plants: ethnobotanical, phytochemical, and pharmacological investigations. McKenna then received post-doctoral research fellowships in the Laboratory of Clinical Pharmacology, National Institute of Mental Health, and in the Department of Neurology, Stanford University School of Medicine.
James Fadiman ph.d.
Fadiman received a Bachelor of Arts degree from Harvard University in 1960 and a Master's degree and a doctorate (both in psychology) from Stanford University – the PhD in 1965. While in Paris in 1961, his friend and former Harvard undergraduate adviser, Ram Dass, introduced him to psychedelics. In 1963, Fadiman worked at Stanford's Augmentation Research Center, a division that did research on networked computing. Fadiman was also part of the team in the psychedelics in problem-solving experiment at the International Foundation for Advanced Study, which was abruptly halted in 1966. He currently is currently researching the effects of micro-dosing psilocybin and LSD.
WILLIAM A. RICHARDS, PH.D.
PSYCHOLOGIST, John Hopkins University
William A. Richards is a psychologist in the Psychiatry Department of the Johns Hopkins University School of Medicine, Bayview Medical Center, currently pursuing research with entheogens, and also a clinician in private practice in Baltimore. His graduate degrees include M.Div. from Yale Divinity School, S.T.M. from Andover-Newton Theological School and Ph.D. from Catholic University, as well as studies with Abraham Maslow at Brandeis University and with Hanscarl Leuner at Georg-August University in Göttingen, Germany, where his involvement with psilocybin research originated in 1963. From 1967 to 1977, he pursued psychotherapy research with LSD, DPT, MDA and psilocybin at the Maryland Psychiatric Research Center, including protocols designed to investigate the promise of entheogens in the treatment of alcoholism, severe neuroses, narcotic addiction and the psychological distress associated with terminal cancer, and also their use in the training of religious and mental-health professionals. From 1977-1981, he was a member of the psychology faculty of Antioch University in Maryland. His publications began in 1966 with “Implications of LSD and Experimental Mysticism,” coauthored with Walter Pahnke, and published in the Journal of Religion and Health.
Dr. TerreNCE Early
Dr. Early has spent nearly 30 years working with patients who have treatment-resistant psychiatric disorders, including over a decade of research into the development of new forms of treatment in academic centers such as Washington University, the University of Texas Medical Branch in Galveston, and the Baylor College of Medicine. One insight gained was the realization that there are treatments that have been proven to work in placebo-controlled trials that still do not get regularly used, primarily because they are not the newly-patented medications that are aggressively marketed to the public and to physicians.
erika dyck, PH.D.
HISTORIAN, University of Saskatchewan
Erika Dyck grew up in Saskatoon and started a BA in history at the University of Saskatchewan before transferring to Dalhousie to complete her degree in History. She returned to Saskatchewan and completed a Masters degree with Valerie Korinek in 2000. After a year working at a law firm in Toronto, she began her PhD in History of Medicine at McMaster University. Her dissertation has now been published as a book, Psychedelic Psychiatry: LSD from Clinic to Campus by Johns Hopkins University Press (2008), republished by the University of Manitoba Press in 2011. Her 2013 book Facing Eugenics was shortlisted for the Canada Prize in Social Sciences and for the John A. Macdonald Prize.
David e. nichols, PH.D.
pharmacologist & medicinal chemist
Previously the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology at Purdue University, Nichols has worked in the field of psychoactive drugs since 1969. While still a graduate student, he patented the method that is used to make the optical isomers of hallucinogenic amphetamines. He is the founding president of the Heffter Research Institute. In 2004 he was named the Irwin H. Page Lecturer by the International Serotonin Club, and delivered an address in Portugal titled, "35 years studying psychedelics: what a long strange trip it's been." Among pharmacologists, he is considered to be one of the world's top experts on psychedelics. Nichols's other professional activities include teaching medicinal chemistry and molecular pharmacology at Purdue University in West Lafayette, IN, and teaching medical students at the Indiana University School of Medicine.
Dr. cole marta
Dr. Marta completed undergraduate studies at UC – Santa Cruz majoring in molecular, cellular, and developmental biology where he graduated with highest honors in the major, with a focus on genetics. After graduating, he was a Junior Specialist in a Howard Hughes Medical Institute laboratory studying neurogenetics in the model organism C. Elegans.
He earned his MD from Chicago Medical School. Inspired by faculty and clinical experiences at Elgin State Hospital, Marta pursued and completed his residency at UCLA San Fernando Valley Veteran Association Psychiatry Training Program. While there, he focused on psychotherapy and psychopharmacology pertaining to mental illness. Marta also participated in cutting-edge research at UCLA related to mood, anxiety, substance use, and posttraumatic stress disorder.
He is am committed to working with adults to improve their overall well-being.
MUSHROOM EXPERT & PSILOCYBIN FACILITATOR
Eric holds a Master’s Degree in Education, is the first Indiana State Certified Wild Mushroom Expert, and is the founder of PLEDG, (Psychedelic Liberation Education Discipline and Guidance), a U.S. based non-profit for psychedelic research and education. He is the founder of MycoMeditations, a week long psilocybin retreat in Jamaica where mushrooms are legal.
EDUARDO SCHENBERG PH.D.
NEUROSCIENTIST & PHARMACOLOGIST
Eduardo Schenberg is General Director at Instituto Plantando Consciência, a non-profit dedicated to studies about consciousness in its many different aspects, from neuroscience to the noosphere. Holds a bachelor degree in biomedical science and a Master’s in psychopharmacology (UNIFESP 1999-2005) and a PhD in neuroscience (USP, 2006-2010). Since his post/doctoral studies (UNIFESP and Imperial College London) he started research about the effects of psychedelic substances like LSD and ayahuasca in the human brain; and about the salutary aspects and therapeutic potential of non-ordinary states of consciousness. Current projects include treatment for drug dependence with ibogaine and for PTSD with MDMA-assisted psytchotherapy, all done in professional therapeutic contexts following ethic principles.
AMANDA FIELDING PH.D.
DRUG POLICY REFORMER
Through the Beckley Foundation, Feilding initiates, directs, and supports scientific research investigating psychoactive substances, such as cannabis, psychedelics (LSD, psilocybin, ayahuasca, DMT, 5-MeO-DMT) and MDMA . She has co-authored over 50 scientific papers in peer-reviewed journals.
Known to be one of the pioneers of the renaissance of psychedelic research, with the New Scientist calling her the "Queen of Consciousness", she has initiated several ground-breaking research projects. Of note is a study investigating the efficacy of using psilocybin as an aid to psychotherapy in overcoming depression and nicotine addiction, a brain imaging study investigating the effects of psilocybin and MDMA on cerebral blood supply, an examination of the effects of cannabis on creativity and of the importance of the THC/CBD ratio in mental health, and the first brain imaging study investigating the effects of LSD on the brain.
DRUG POLICY REFORMER
Emanuel Sferios is an activist, educator and harm reduction advocate. Founding DanceSafe in 1998 and starting the first laboratory pill analysis program for ecstasy users that same year (now hosted at Ecstasydata.org), Emanuel pioneered MDMA harm reduction services in the United States. His MDMA Neurochemistry Slideshow has been viewed over 30 million times and remains a primary educational resource for physicians, teachers, drug abuse prevention counselors and MDMA users alike. Emanuel resigned from DanceSafe in 2001 and went on to work in other areas of popular education and harm reduction. He has recently come back as a volunteer. Oh! And he’s making a movie.
mary cosimano MSW
Mary Cosimano, MSW, is currently with the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine and has served as study guide and research coordinator for the psilocybin studies for over a decade. During that time she has served as a session guide for the psilocybin studies and has conducted over 200 sessions. She has worked as a clinician teaching individual and group meditation to breast cancer patients in research at Johns Hopkins, as a behavior modification counselor for weight loss, and has 15 years of experience with direct patient care as a hospice volunteer. Ms. Cosimano has been extensively involved in all five psilocybin studies, as well as Salvia divinorum and dextromethorphan studies conducted at Johns Hopkins. She will provide her perspective as primary guide and study coordinator in the Johns Hopkins Psilocybin Studies.
He is an aikidoka (Aikido practitioner). He is academically formed in the therapeutic use of the non-ordinary states of consciousness. He has also trained and coordinated psychological emergency assistance teams in multitudinous festive events (Kosmicare - Portugal). He facilitates Holotropic Breathwork workshops in Barcelona and Switzerland. He works as a psychologist in Barcelona.
After teaching in Maine for five years, Marcela moved to attend Graduate school at the University of North Carolina in Greensboro. I received an MFA in painting and taught college art for five years. During that time I headed many projects with underprivileged populations working on healing trauma through art. It was then that I understood the power of healing by simply being seen, and how emotions connect us to one another. She attended Naropa University where Marcela received an MA in Transpersonal Psychology. She now has a private practice in Boulder, CO.